ClinicalTrials.gg
Not yet recruitingNCT04229758Restart tICrHUpdated May 19, 2021

Restarting Anticoagulation After Traumatic Intracranial Hemorrhage

A Phase 3 interventional study of Anticoagulants in Hemorrhage, Intracranial Hemorrhages and Bleeding, sponsored by University of Texas at Austin. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-19.

Primary conditionIntracranial HemorrhagesRegistry: HemorrhageReclassifiedWhy we changed it
Registry
Hemorrhage — the first condition term the registry derived for this study.
ClinicalTrials.gg
Intracranial Hemorrhages
Why
  1. The study's listed conditions name Intracranial Hemorrhages, a narrower term within Hemorrhage.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Texas at Austin · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 63 studies in Intracranial Hemorrhages with a site in United States — 17 open to participants now, 21 under way, 1 of them phase 3. Intracranial Hemorrhages · United States.

Planned enrollment
Largest of 43
1,100 · median 50
Started
2021
with 1 other
Phase 3
5 of 63
1 open now
Primary completion
2026-12
later than 3 of 20 live
Registered
38th of 63
by date

Among the 63 studies in Intracranial Hemorrhages with a site in United States, this one has the largest planned enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2021, is one of 5 in phase 3, reaches primary completion later than 3 of the 20 other live ones, and was the 38th registered.

Intracranial Hemorrhages

211 studies on the registry are indexed under Intracranial Hemorrhages; 62 are open to participants now.

Browse Intracranial Hemorrhages studies →

Open to participants now

17 of the 63 studies in Intracranial Hemorrhages with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Intracranial Hemorrhages studies recruiting now, 27 (63%) set no upper age limit and 5 (12%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Intracranial Hemorrhages with a site in United States, or all of them as a file.
02

Study summary

Primary Objective:

To identify the optimal interval to restart oral anticoagulation after traumatic intracranial hemorrhage that will minimize thrombotic events and major bleeding by performing a response adaptive randomized (RAR) PROBE clinical trial of restarting in anticoagulant-associated traumatic intracranial hemorrhage patients, comparing restart at 1 week to restart at 2 weeks or at 4 weeks, with a primary composite outcome of major thrombotic events and bleeding.

Primary Outcome: 60-day composite of thromboembolic events, defined as DVT, pulmonary emboli, myocardial infarctions, ischemic strokes and systemic emboli, and bleeding events defined as non-CNS major bleeding events (modified BARC3 or above) and worsening index tICrH or new intracranial hemorrhage (ICrH).

Secondary objectives of this trial include:

  1. To use the Trauma Quality Improvement Program (TQIP) of the American College of Surgeons - Committee on Trauma (ACS-COT), a well-established and highly respected trauma center oversight mechanism, to translate findings of the trial into practice in a closed loop.
  2. To establish a relationship between time of restarting and overall secondary events, i.e. a dose response, that favors early restarting (1 week is better than 2 weeks and 2 weeks is better than 4 weeks.
  3. To explore patient centered utility weighting of thrombotic versus bleeding composite endpoint components by: A) 60-day Disability Rating Scale (DRS) 24,25 and modified Rankin Scale (mRS)26; B) Trial patient-reported standard gamble utilities including by race, gender and ethnicity.
  4. To explore the composite without DVT in the thrombotic component
Read the detailed description

Title: Restart tICrH Protocol Synopsis A Prospective Randomized Open Label Blinded Endpoint Response Adaptive Clinical Trial of Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Hemorrhage

Objectives: To identify the optimal interval to restart oral anticoagulation after traumatic intracranial hemorrhage that will minimize thrombotic events and major bleeding by performing a response adaptive randomized (RAR) clinical trial of restarting in anticoagulant-associated traumatic intracranial hemorrhage patients, comparing restart at 1 week to restart at 2 weeks or at 4 weeks, with a primary composite outcome of major thrombotic events and bleeding.

Hypotheses: We hypothesize that restarting an oral anticoagulant at one week after anticoagulant-associated traumatic intracranial hemorrhage, compared to delayed restarting, reduces a composite outcome of major thrombotic events and major bleeding.

Study design Prospective, response adaptive randomized, open-label, blinded end-point (PROBE), 40 center national trial Study population -- Approximately 1100 participants with traumatic intracranial hemorrhage and an indication for Direct Oral Anticoagulant Main inclusion criteria

  1. Clinician intent to restart a Direct Oral Anticoagulant (DOAC) after anticoagulant-associated traumatic intracranial hemorrhage and equipoise concerning restart of anticoagulation at the specified time intervals.
  2. Acute traumatic intracranial hemorrhage on anticoagulation for Atrial Fibrillation (AF) or Venous Thromboembolism (VTE)
  3. Patient is higher risk for stroke or other thrombotic events as witnessed by having a CHA2DS2-VASc score of > 3
  4. DOAC will be prescribed at label dose with label adjustments for creatinine clearance. DOAC will be at continuation dose, i.e., not initial therapy high doses in the setting of VTE.

Main exclusion criteria

  1. Mechanical Valve/Ventricular Assist Device (excludes 1%)
  2. SDH >8 mm maximum width or any midline shift at any time point or more than one SDH (excludes 10%)
  3. Physician plan to start/restart antiplatelet therapy during trial period (excludes 5%)
  4. Abbreviated Injury Scale other than head >3 (excludes 10%)
  5. Pregnancy (excludes 0%: median age 81, range 58-99)
  6. Inability to understand need for adherence to study protocol
  7. Renal function below DOAC label exclusions
  8. Any active pathological bleeding (no acute blood most recent CT)
  9. Hypersensitivity to drug or other label contraindication
  10. Any bleeding that the investigator deems unsafe to restart DOAC at 1 week post injury, or conversely unsafe to hold DOAC to 4 weeks
  11. Completion of DOAC therapy expected prior to 60-day primary endpoint, e.g., 3-6-month VTE treatment
  12. Concomitant strong inducers/inhibitors of p-gp and CYP3A4
  13. Low body weight (\<45kg)
  14. Inability to swallow

Interventions: • The trial will randomize patients with anticoagulant-associated traumatic intracranial hemorrhage to restart DOAC at 1 week or 2 weeks or 4 weeks, using an adaptive randomization algorithm that increases the probability of patients being randomized to treatment arms with lower event rates.

Primary efficacy outcome: A 60-day composite outcome that includes the following clinical events:

A. Bleeding Events Worsening tICrH/new ICrH

1)Hematoma expansion/new ICrH lesion on imaging 2)causing objective change in clinical status and 3)leading to stop of anticoagulation (must include all three).

Extracranial Major bleeding BARC3a or above definition. B. Thrombotic events Venous Thromboembolism (VTE) It is defined as a clinical diagnosis of acute proximal (popliteal and above) deep vein thrombosis or pulmonary embolus confirmed on imaging (compression ultrasound or venogram for DVT, CT angiography, other angiography or ventilation/perfusion scan for PE) by a radiologist qualified to interpret the scans in a timely manner. If the radiologist cannot or does not attest to acute versus chronic thrombus, the Adjudication Committee will make this determination according to its charter.

Myocardial Infarction (MI) Fourth Universal Definition of Myocardial Infarction.

Stroke New focal neurologic deficit consistent with ischemic stroke and confirmed by a stroke specialist or brain imaging. Brain imaging must be performed but need not be positive if the stroke specialist (neurology, neurosurgery or internal medicine) deems a clinically probable stroke.

Systemic Embolism A clinical diagnosis of extracranial infarction associated with likely thromboembolism and documented by angiography or surgery in the absence of atherosclerotic occlusion.

Cardiovascular death non bleeding Death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to cardiovascular procedures, and death from other cardiovascular causes 45. A patient who has both this outcome and another thrombotic outcome will only be counted once as this outcome.

Secondary outcomes: Modified Rankin Scale and Disability Rating Scale

Safety outcomes: Incorporated in composite as thrombotic and bleeding events

Statistical analysis: All interim and final analyses will be conducted on the primary outcome, the composite 60-day outcome of thromboembolic events and recurrent hemorrhage. Both thrombotic and bleeding outcomes will be modeled as a function of the three treatment arms in a dose (time)/response (events composite) model. Two Bernoulli models will be used to estimate thromboembolism and recurrent hemorrhage. Each of the rates for the Bernoulli values by dose are θd and δd for thromboembolism and recurrent hemorrhage respectively. These rates are combined to provide a utility function Ud=-θd-δd, so higher values of Ud correspond to the better dose to establish specifically whether at a week is best and generally whether earlier is better than later.

Sample size: 1100

Clinical sites: Approximately 40 trauma center clinical sites in the US.

Recruitment period: Approximately 60 months

Follow-up period: Participants will be followed weekly for 60 days, the study end date.

Special procedures: N/A

Coordinating centers: Seton Dell Medical School Stroke Institute, Coalition for National Trauma Research, Kansas University Medical Center

Sponsor: Seton Dell Medical School Stroke Institute

03

Conditions studied

  • Hemorrhage
  • Intracranial Hemorrhages
  • Bleeding
  • Trauma

Browse trials for

Keywords

  • Anticoagulation
  • Anticoagulant
  • Anticoagulants
  • Restart
  • Delay
  • Hemorrhage
  • ICH
  • SAH
  • SDH
  • DOAC
  • NOAC
  • apixaban
  • rivaroxaban
  • edoxaban
04

In context

Intracranial Hemorrhages Reclassified

211 studies on the registry are indexed under Intracranial Hemorrhages; 62 are open to participants now.

This study's planned enrollment of 1,100 is above the median of 87 across 118 interventional studies indexed under Intracranial Hemorrhages.

Browse Intracranial Hemorrhages studies →

Lead sponsor

University of Texas at Austin is the lead sponsor of 328 studies on the registry; 79 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.

Compared within Intracranial Hemorrhages, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hemorrhage. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Entry into the trial is primarily driven pragmatically by clinician intent to restart a Direct Oral Anticoagulant (DOAC) after anticoagulant-associated traumatic intracranial hemorrhage and equipoise concerning restart of anticoagulation at the specified time intervals. DOAC will be at label dose with label adjustments for . DOAC will be at continuation dose, i.e. not initial therapy high doses in the setting of VTE.

  1. Acute traumatic intracranial hemorrhage on anticoagulation for Atrial Fibrillation (AF) or Venous Thromboembolism (VTE) or both (2,500 patients per year at our 40 sites)
  2. Patient is higher risk for stroke or other thrombotic events as witnessed by having a CHA2DS2-VASc score of > 3 (at least 3 of the following risk factors: age greater than 65,( age > 75 counts for two points), history of stroke or , history of heart failure, history of diabetes, history of atherosclerotic vascular disease, female gender, history of hypertension) (Excludes 20% or 500 patients per year)

Exclusion criteria

Exclusion Criteria:

  1. Mechanical Valve
  2. Ventricular Assist Device (VAD)
  3. SDH >8 mm maximum width or any midline shift at any time point or more than one SDH
  4. Physician plan to start/restart antiplatelet therapy during trial period
  5. Acute Injury Score other than head >=3
  6. Pregnancy
  7. Inability to understand need for adherence to study protocol
  8. Renal function below DOAC label exclusions
  9. Any active pathological bleeding (e.g. no acute blood on most recent CT)
  10. to drug or other label
  11. Any bleeding that the investigator deems unsafe to restart DOAC at 1 week post injury, or conversely unsafe to hold DOAC to 4 weeks
  12. Expected completion of DOAC therapy expected prior to 60 day primary outcome, e.g. 3-6 month VTE therapy
  13. Concomitant need for strong inducers/inhibitors of p-gp and
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

06

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,100 participants (estimated)

Study arms

  • Experimental
    1 week

    Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.

    Drug: Anticoagulants

  • Experimental
    2 weeks

    Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.

    Drug: Anticoagulants

  • Experimental
    4 weeks

    Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.

    Drug: Anticoagulants

Interventions

  • DrugAnticoagulants

    DOAC for the prevention of thromboembolic events in patients with non-valvular AF or VTE.

07

What researchers measure

Primary outcomes

  1. 60 Day Composite of Thrombotic and Bleeding Events

    Composite of Thrombotic events, defined as DVT, PE, MI, Ischemic Strokes, and systemic emboli, cardiovascular death along with bleeding events defined as non-CNS major bleeding, worsening index tICrH, or new intracranial hemorrhage.

    Time frame: 60 days following index bleeding event

Secondary outcomes

  1. 60 Day Disability Rating Scale (1-29 with 29 being worse)

    DRS is a scale to measure disability after an injury

    Time frame: 60 days following index bleeding event

  2. 60 Day Modified Rankin Scale (1-6 with 6 being worse)

    The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.

    Time frame: 60 days following index bleeding event

  3. Standard Gamble Patient Reported utilities for endpoints

    Performed prior to randomization and immediately after each endpoint

    Time frame: pre-randomization and after endpoints

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: Yes — Sharing of data generated by this project is an essential part of our proposed activities. Following study completion, the DCC staff will follow National Trauma Research Repository (NTRR) and NHLBI's Biologic Specimen and Data Repository Information Coordinating Center (BioLLINCC) policies to upload the study's final de-identified data set, supporting documentation (data dictionary, protocol, consent form, data analysis plans) and any manuscripts. The final data set will be a csv file upload that is consistent with the NTRR data element attributes and characteristics.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: After publication of primary manuscript

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2021; primary completion for Dec 2026, 62 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2020
First posted
Jan 18, 2020
StartEst.
Oct 2021
Primary completionEst.
Dec 2026
CompletionEst.
Feb 2027
Last update
May 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04229758
Responsible party
Truman J Milling Jr (Associate Professor of Neurology, University of Texas at Austin) — Principal investigator
First posted
Jan 18, 2020
Start date
Oct 2021 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
May 19, 2021

Study contacts

Truman J Milling, MD
Contact
tmilling@ascension.org
5124969742
Patrick Lawrence
Contact
patrick.lawrence@austin.utexas.edu
Truman J Milling, MD
principal investigator · Seton Dell Medical School Stroke Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion